Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 31, 2015

BioOutsource Opens New Facility in Glasgow

The investment doubles the company’s capacity to meet increasing demand for its biologics contract testing and biosimilar characterization services.

BioOutsource, part of Sartorius Stedim Biotech Group, has opened a new facility in Glasgow. The investment follows the increasing demand for the company’s biologics contract testing and biosimilar characterization services. The new facility doubles BioOutsource’s capacity for future growth and will create approximately 50 new jobs for scientific and technical professionals in the next six months, according to the company.

Source: BioOutsource


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.